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Background: Epileptic encephalopathies are a devastating group of neurological
conditions in which etiological diagnosis can alter management and clinical out-
come. Exome sequencing and gene panel testing can improve diagnostic yield but
there is no cost-effectiveness analysis of their use or consensus on how to best
integrate these tests into clinical diagnostic pathways.
Methods: We conducted a retrospective cost-effectiveness study comparing trio
exome sequencing with a standard diagnostic approach, for a well-phenotyped
cohort of 32 patients with epileptic encephalopathy, who remained undiagnosed
after “first-tier” testing. Sensitivity analysis was included with a range of commer-
cial exome and multigene panels.
Results: The diagnostic yield was higher for the exome sequencing (16/32; 50%)
than the standard arm (2/32; 6.2%). The trio exome sequencing pathway was
cost-effective compared to the standard diagnostic pathway with a cost saving of
AU$5,236 (95% confidence intervals $2,482; $9,784) per additional diagnosis; the
standard pathway cost approximately 10 times more per diagnosis. Sensitivity
analysis demonstrated that the majority of commercial exome sequencing and
multigene panels studied were also cost-effective. The clinical utility of all diag-
noses was reported.
Conclusion: Our study supports the integration of exome sequencing and gene
panel testing into the diagnostic pathway for epileptic encephalopathy, both in
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terms of cost effectiveness and clinical utility. We propose a diagnostic pathway
that integrates initial rapid screening for treatable causes and comprehensive geno-
mic screening. This study has important implications for health policy and public
funding for epileptic encephalopathy and other neurological conditions.
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1 | INTRODUCTION
Infantile-onset epileptic encephalopathy (EE) is a descrip-
tive term for a group of severe epilepsy disorders character-
ized by early onset of drug-resistant seizures, with
developmental stagnation or regression (Berg et al., 2010).
The estimated incidence of EE is 4.3 per 10,000 live births
per year (Hino-Fukuyo et al., 2009). EE results in a high
burden of care for families and the health service (Beghi
et al., 2005), a significant risk of comorbidity, and a short-
ened life span (Khan & Al Baradie, 2012). Diagnosis is
challenging as etiologies are numerous with significant
phenotypic overlap; these include nongenetic causes as well
as over 200 monogenic seizure disorders, inborn errors of
metabolism, and intellectual disability syndromes (McTa-
gue et al., 2016). The benefits of a timely etiological diag-
nosis are clear (Reif et al., 2017): allowing personalized
management guiding choice of antiepileptic (Consortium E,
2015) or metabolic treatment (van Karnebeek et al., 2014),
health surveillance for recognized comorbidities, accurate
estimation of chance of recurrence in the family, reproduc-
tive options counseling, provision of “closure,” and access
to specific support groups for families (Berkovic, 2015).
A typical diagnostic approach for EE encompasses two
steps: first- and second-tier assessments. First-tier assess-
ment includes neurological and clinical genetics review,
screening for metabolic disorders, neuroimaging, neuro-
physiology, chromosomal microarray, and targeted genetic
testing for clinically suspected conditions (Kamien et al.,
2012; Mercimek-Mahmutoglu et al., 2015). This allows for
diagnosis of EE secondary to cortical malformations/hem-
orrhage or strokes, perinatal hypoxia–ischemia, focal
lesions amenable to surgery, some metabolic and mitochon-
drial disorders, clinically recognizable syndromes such as
tuberous sclerosis, pathogenic chromosomal copy number
variants, and electroclinical syndromes associated with a
particular gene such as SCN1A-related Dravet syndrome
(MIM 607208). However, 40%–50% of patients with EE
remain undiagnosed after first-tier assessment (Osborne
et al., 2010; Poulat et al., 2014). Second-tier assessment
involves repeated clinical assessments, further neuroimag-
ing and metabolic studies, and sequencing of individual
genes (Kamien et al., 2012; Mercimek-Mahmutoglu et al.,
2015). This approach often represents a diagnostic odyssey
for patients, their families, and clinicians: invasive, costly,
time-consuming, and with low diagnostic yield (<10%)
(Mercimek-Mahmutoglu et al., 2015).
The low diagnostic yield of standard second-tier testing
reflects the difficulty in targeting genetic testing for EE: it
is increasingly recognized that genes rarely respect the con-
cept of electroclinical syndromes, such as those proposed
by the International League Against Epilepsy ILAE (Berg
et al., 2010). Variants in one gene may cause different
electroclinical syndromes, and conversely each electroclini-
cal syndrome has an ever-growing range of genetic causes
(Gursoy & Ercal, 2016; Mastrangelo, 2015; McTague
et al., 2016; Palmer et al., 2017). In addition, the field is
rapidly changing. OMIM currently lists 56 genetic causes
of infantile onset EE (source: Online Mendelian Inheritance
in Man website accessed June 2017, http://www.omim.org/
phenotypicSeries/PS308350), but there are well over 200
monogenetic conditions in which EE has been reported
(Gursoy & Ercal, 2016). However, there is now a substan-
tial body of work demonstrating that application of high-
throughput sequencing (HTS) via targeted multigene panels
or exome sequencing (ES) improves diagnostic yield in EE
by 20%–40% (Chambers, Jansen, & Dhamija, 2016; Con-
sortium E-R, Project EPG, Consortium EK, 2014; Helbig
et al., 2016; Kwong et al., 2015; Lemke et al., 2012;
Trump et al., 2016); HTS has the potential to minimize this
invasive and expensive “diagnostic odyssey.” Most reports
claim that this implies cost effectiveness (Helbig et al.,
2016; Lemke et al., 2012), but solid health economic data
are lacking.
The closest analysis to a cost-effectiveness study in an
EE cohort was undertaken by Joshi et al. (2016). The
authors reported the cost of first- and second-tier testing
for four patients from three families. This study reported
second-tier standard testing (excluding consultation costs)
for EE of between US$9,015 and US$35,480. However, all
of the patients in Joshi et al.’s study had a genetic diagno-
sis only after exome sequencing, and no patients who may
have had a diagnosis using the standard diagnostic pathway
were included. While this study produces costs of different
testing methods for a small sample of patients, cost effec-
tiveness of ES over a standard diagnostic path cannot be
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inferred as the study only reports on diagnosed patients,
and only those diagnosed by ES. For cost-effectiveness
analysis, data are required from a cohort that encompasses
all patients who incurred costs for exome sequencing,
including patients who did not reach a diagnosis as well
those who received a diagnosis, from both ES and the
comparative standard diagnostic approach.
It is critical to provide timely data about the health costs
of genomic testing in conditions such as EE (Cartwright,
1997) to inform policymakers. However, a prospective
cost-effectiveness study with randomization to standard
versus ES diagnostic pathway would be unethical, given
the well-established clinical benefits of establishing a
molecular diagnosis and the improved diagnostic yield with
ES/multigene panel over standard testing in EE (Helbig
et al., 2016). We thus aimed to supply a cost-effectiveness
analysis of a trio ES approach compared with standard test-
ing, in a well-defined clinical cohort of 32 patients with
EE who were undiagnosed after first-tier testing, using a
well-established counterfactual health economics study
design. With this study design, patients are used as their
own controls and cost-effective comparison is done as if
ES had been done early in the diagnostic pathway. The
deliberate focus of the study was on patients undiagnosed
after first-tier testing, as the most pressing clinical need is
to develop an optimal diagnostic pathway for this group of
patients. The study was performed in a pediatric children’s
hospital and, to our knowledge, is the first to provide a
robust cost-effectiveness study of ES in EE.
2 | SUBJECTS/MATERIALS AND
METHODS
2.1 | Ethical compliance
The research was approved by the ethics committee from
The Sydney Children’s Hospital Network and the Prince of
Wales Hospital Campus, Sydney, Australia (HREC ref no.
13/094).
2.2 | Study design/Patient cohort and
inclusion/exclusion criteria
An overview of the study design is provided in Figure 1.
There were 48 infantile onset EE patients of Sydney Chil-
dren’s Hospital Australia, born between 1 January 2000
and 31 December 2013, who remained undiagnosed after
first-tier assessment and were eligible for enrollment in the
study. All patients were required to fulfill strict diagnostic
criteria for infantile-onset EE based on the current ILAE
definition (Berg et al., 2010): namely they were required to
have (a) drug-resistant epilepsy for a minimum of
6 months, (b) seizure onset accompanied by adverse impact
on development such as developmental stagnation or
regression, (c) an infantile-onset of seizures (before
18 months), and (d) at least one electroencephalogram
(EEG) that was significantly abnormal with diffusely
poorly organized background and marked bihemispheric
epileptogenic activity (e.g., hypsarrhythmia, multifocal).
Proband and parental DNA needed to be available. Patients
were excluded if they had a clear genetic/other etiological
diagnosis previously established on first-tier assessment, for
example, tuberous sclerosis (MIM: 605284), SCN1A-related
Dravet syndrome (MIM 182389), major structural/focal
anomaly on neuroimaging, vascular stroke, head injury,
infection, ischemia, if the primary neurologist or clinical
geneticist were not in agreement with the enrollment of
family in study, or if the patient were already entered into
another research genetic study.
First-tier assessment comprised investigations/consulta-
tions considered appropriate for initial investigation of a
patient with EE regardless of the availability of exome
sequencing (ES), as the results of these could potentially
alter immediate clinical management, and establish a num-
ber of important, and potentially treatable, diagnoses. Con-
sensus regarding first-tier assessment was reached by
consultation with all clinical neurologists of the Paediatric
Neurology Department of SCH using a modified Delphi
approach (Powell, 2003), and was consistent with current
literature recommendations (Kamien et al., 2012; Merci-
mek-Mahmutoglu et al., 2015). Assessments and tests con-
sidered as “first tier” in this study included pediatric
neurology and clinical geneticist consultations, a consulta-
tion with a genetic counselor including the consent process
for genetic testing, brain magnetic resonance imaging
(MRI), a routine 20 min EEG, “first-tier” urine, blood, and
cerebrospinal fluid studies, chromosomal microarray, and
single-gene testing if a single monogenic condition was
specifically indicated by the patient’s phenotype (e.g.,
SCN1A testing if the patient fulfilled diagnostic criteria for
Dravet syndrome). Full details of the first-tier tests and
consultation, with associated costs, are included in
Table S1.
Twelve patients were excluded as informed consent or
sufficient DNA was unable to be obtained and a further
four were excluded as they were enrolled in other research
studies. A cohort of 32 patients remained. Table S2 sum-
marizes the demographic characteristics of the cohort and
phenotypic details of the cohort are provided in Table 1
and in more detail in Table S3. The average age of undiag-
nosed patients entering our study was 46.6 months.
Thirty-two patients included in the study all underwent
first-tier testing and then standard second-tier diagnostic
testing including detailed metabolic studies, further diag-
nostic neuroimaging and single-gene testing as determined
by the involved clinicians (details and costs of first- and
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second-tier tests provided in Table S1). Two of the 32
patients (individuals 15 and 16 in Table 1) received a diag-
nosis after standard second-tier assessment, and these indi-
viduals did not proceed to exome sequencing. The
remaining 30 individuals were enrolled in trio ES. Trio ES
(proband and both parents) was conducted at the South
East Area Laboratory Services (SEALS) Genetics labora-
tory and the Kinghorn Centre for Clinical Genomics
(KCCG) as previously described (Palmer et al., 2015).
Informed consent for ES was obtained.
Candidate variants identified on trio ES were confirmed
using Sanger sequencing. Assessment of the potential
pathogenicity of candidate variants followed international
guidelines (MacArthur et al., 2014; Richards et al., 2015).
This included, when appropriate, a combination of segrega-
tion studies in the extended family, diagnostic functional
studies, and in some circumstances, research functional
studies (molecular biology, cell culture, and animal stud-
ies). Details of evidence for each pathogenic/likely patho-
genic variant are in Table S2 and approach to variant
classification provided in Figure 2. A diagnostic report was
issued for pathogenic and likely pathogenic findings that
were returned to the family by the involved clinical genet-
ics and neurology physicians.
2.3 | Diagnosis-related cost ascertainment
The costs of all diagnostic-related test and consultations
were collected for each of the 32 patients entering the
study (all tests and costs detailed Table S1). Case files,
pathology databases, public hospital, and commercial costs
were interrogated to collect diagnostic costs for each pro-
band, and this information was entered in a deidentified
database (ethics approval LNR/13/SCHN/112). Costs
included the billed cost of the test, courier costs, work-
force costs associated with diagnostic procedures, patient
admission for diagnostic tests such as imaging, and the
fractional cost of specialist consultations related to diagno-
sis. We included costs related to diagnostically available
functional tests that assisted in the assessment of
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FIGURE 1 Flowchart of study design. EE, epileptic encephalopathy; ES, exome sequencing; DNA, deoxyribonucleic acid
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pathogenicity of novel findings, for example, the cost of a
repeat purine and pyrimidine screen to confirm a diagnosis
of ADSL-related disorder (MIM 103050) in patient 1. Func-
tional validation of novel variants conducted in the collabo-
rative research arena that did not entail direct institution or
patient-related costs were not included. Health costs col-
lected for the trio ES pathway included DNA extraction,
and all costs related to sequencing, the work costs of a
Medical Genomicist to prioritize variants and of a genetic
pathologist to assess pathogenicity and compile a diagnos-
tic grade report.
2.4 | Cost-effectiveness analysis
In order to analyze the cost effectiveness of an exome diag-
nostic model (EDM) over a standard diagnostic model
(SDM) we compared diagnostic yields and cost of diagno-
sis between the two models using a counterfactual
approach similar to that described in Stark et al. (2017).
This counterfactual approach allows comparison of diag-
nostic yields and costs under the SDM arm (i.e., first-tier
assessment and then standard second-tier assessment) and
the actual/expected diagnostic yields and costs under the
EDM (i.e., first-tier assessment and then second-tier assess-
ment including trio ES, Sanger confirmation of pathogenic/
likely pathogenic variants, and adjunctive tests required to
screen for causes of EE not readily diagnosable by ES: see
Figure 1) for the same individual. Therefore, for this
approach, the two patients who received a diagnosis in the
SDM arm (individuals 15 and 16 in Table 1) were included
as having received a diagnosis under the EDM, which was
a reasonable assumptions as the CDKL5 variant detected in
patient 15 in the SDM was in a region adequately covered
by the ES platforms used, and that screening for the com-
mon expansions in exon 2 of ARX is included in the EDM
arm, which would have allowed detection of the ARX
expansion variant present in patient 16 (Table 1). There-
fore, for the health economic analysis both groups have a
denominator of 32, although only 30 patients needed to
proceed to ES.
We compared the average cost per patient and the aver-
age cost per diagnosis, between the SDM and the EDM.
Both first- and second-tier costs were included in both
models. We also estimated an incremental cost per addi-
tional diagnosis (Drummond, Sculpher, Claxton, Stoddart,
& Torrance, 2005) for the trio ES in the second-tier testing
pathway over the standard second-tier testing pathway. We
used bootstrap methods to estimate the uncertainty associ-
ated with outcomes. Bootstrapping is a widely used method
to derive confidence intervals for outcomes (such as the
incremental cost per additional diagnosis) for which the
underlying distributions are not clear. Rather than making
assumptions about the underlying distribution, bootstrap-
ping relies on repeated samples drawn with replacement
from the original data to create a sampling distribution
(Drummond et al., 2005). Using this method, we created
1,000 replicated datasets and estimated outcomes such as
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ST, standard testing; T, tolerated.
192 | PALMER ET AL.
incremental cost per additional diagnosis for each of the
1,000 replicated datasets. This generated 1,000 estimates of
each outcome, which provided the sampling distribution of
each outcome. Based on these sampling distributions, we
estimated 95% confidence intervals for the outcomes using
the percentile method (Briggs, Wonderling, & Mooney,
1997). Results were presented as scatter plots on a cost-
effectiveness plane. All analyses were performed in Micro-
soft Excel except for bootstrap simulations and confidence
interval estimation, which were undertaken in SAS (SAS
Institute, Cary, NC, USA) version 9.4.
2.5 | Sensitivity analysis
As a sensitivity analysis, we substituted the price of trio
ES provided by the in-house SEALS service by the price
provided by four different commercial laboratories: Gen-
eDx, Maryland, United States; Fulgent Diagnostics, Cali-
fornia, USA; Genome Diagnostics Nijmegen, Nijmegen,
The Netherlands; and Centogene, Rostock, Germany, con-
verted to Australian dollars (AU$) based on the exchange
rate published by the Reserve Bank of Australia for 1 July
2016 (http://www.rba.gov.au/statistics/tables/xls-hist/2014-
current.xls). Costs of these platforms are detailed in
Table S1. To allow cost-effectiveness analysis, an assump-
tion was made that the diagnostic yield would be equiva-
lent for all platforms, although it is appreciated that
diagnostic yields may differ from company to company
due to differences in, for example, sequencing bioinfor-
matic methodology and variations in variant analysis and
interpretation (Berg et al., 2017).
Costs were also assessed for an alternative high-
throughput sequencing (HTS) pathway where a commercial
HTS EE panel was used instead of trio ES: the Courtagen
EpiSeek Comprehensive (471 epilepsy-related genes:
Courtagen Life Sciences Inc., Massachusetts, USA) and the
Fulgent Diagnostics EE panel (133 EE-related genes).
Costs of these panels as of 1 July 2016, converted to AU$
as above, are detailed in Table S1. To allow cost-effective-
ness analysis, the anticipated diagnostic yield for each
panel was derived, using the assumption that if the gene
was included in the HTS panel, the pathogenic variant
detected in our cohort would be detected and therefore a
diagnosis would be made for that patient.
Trio exome sequencing (30 probands, 60 parents), Sequence alignment (BWA) and variant calling (GATK).
Clinical Grade genomic analysis
Variant Filtering (Gemini): coding or regulatory single nucleode/indel variants present at frequency < 1% in the general populaon (databases 
ExAC/GnoMAD) that are either putave loss of funcon (stop or start codon, essenal splice site, frameshi inserons or deleons), o r non-synonymous 
missense variants
Variant in newly described or candidate gene (known neurocognive gene or brain expressed gene 
with plausible role neuronal funcon/development (literature search, protein interacon analysis)?
Assessment of pathogenicity:
• Previously reported pathogenic variant (literature and curated database search, e.g. ClinVar)
• Loss of funcon  variant when those variants are previously described as causave EE 
• Missense variants (when that those variants are previously described as causave of EE) predicted to be pathogenic based on evoluonary conservaon, 
likely effect on protein structure (e.g. HOPE analysis), in silico pathogenicity predicon tools (e.g. CADD, SIFT, Polyphen2), supporve diagnosc funconal 
studies (e.g. metabolic studies) and family segregaon (e.g. de novo/compound heterozygous /homozygous)
Variant in well established EE gene within 
manually curated gene lists?
Meets ACMG based criteria for likely pathogenic/pathogenic variant?
Sanger confirmed? 
Agreement in MDT phenotype fits genotype?
Diagnosc report and result disclosure to family and physician team. Targeted 
management, genec counselling, access support groups/ongoing research.
Variant of uncertain significance
Further validaon of pathogenicity
- Expert advice/ enter into MatchMaker
Exchange to find more cases with matching 
phenotype and genotype.
- Further segregaon in family.
- Collaborave animal/cellular funconal 
studies when required.





























FIGURE 2 Flowchart of exome sequencing analysis. ACMG, American College of Medical Genetics; BWA, Burrows–Wheeler Alignment;
EE, epileptic encephalopathy; ExAC, exome aggregation consortium; GATK, genome analysis toolkit; GnomAD, genome aggregation database;
indel, insertion deletion; MDT, multidisciplinary team meeting
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3 | RESULTS
Results were considered primarily in terms of comparison
of diagnostic yield and cost effectiveness of the two diag-
nostic models.
3.1 | Diagnostic yield
The diagnostic yield for the standard diagnostic arm was 2/
32 (6.2%) compared to 16/32 (50%) for the in-house “trio
ES” arm (variants detected listed in Table 1 additional
detail in Table S3), which, as discussed above, is under the
assumption that both of the genetic diagnoses made in the
SDM arm would have also been made in the EDM arm.
Ten (56%) of 18 pathogenic/likely pathogenic variants (in-
cluding compound heterozygous variants in two individu-
als) were novel. The clinical utility of each finding is
shown in Table 1. Anticipated diagnostic yields for our
cohort for the two commercial EE panels included were 9/
32 (28%) for the Courtagen panel and 12/32 (37.5%) for
the Fulgent panel.
3.2 | Health costs of standard versus trio ES
pathway
The average total cost of diagnosis (first- and second-tier
tests) per patient for the standard pathway was AU$11,828
(95% CI: $10,677; $13,027) compared to AU$9,537 (95%
CI: $9,412; $9,684) for the in-house ES pathway. Given
the improved diagnostic yield of the ES pathway (50%
compared with 6.3%), this meant that the average cost of
testing per diagnosis for the standard pathway was AU
$189,243 (95% CI: $72,703; $406,142) compared to AU
$19,074 (95% CI: $14,421; $27,969) for the ES pathway
(i.e., the standard pathway cost about 10 times more per
diagnosis). The ES pathway proved to be cost-saving com-
pared to the standard pathway, with a cost saving of AU
$5,236 (95% CI: $2,483; $9,784) per additional diagnosis.
The cost-effectiveness plane (Figure 3) indicates that the
trio ES diagnostic pathway is dominant (i.e., cost saving
with a higher diagnostic rate), compared to the standard
diagnostic pathway for all 1,000 bootstrapped replicated
datasets.
3.3 | Health costs for different commercial
exome and high-throughput sequencing panels
Anticipated costs of substituting our in-house platform with
four commercial trio ES platforms (Table 2) and the cost-
effectiveness plane are provided (Figure 3). The ES path-
way was dominant (additional diagnoses while being cost
saving) compared to the standard pathway for 100% of
bootstrapped replicated datasets utilizing the Centogene ES
platform, 97.2% of replicated datasets utilizing the Nijme-
gen ES platform and 96.1% of the replicated datasets using
the ES Fulgent platform. GeneDx was the most expensive
commercial platform analyzed, with both an increased diag-
nostic yield and an increased cost per patient compared to
standard testing; translating to an increased cost of $13,113
(95% CI $8,610; $23,728) per additional diagnosis.
Costs anticipated when substituting two commercial
HTS EE panels into the counterfactual arm are provided
(Table 2) and the cost-effectiveness plane is shown (Fig-
ure 4). Both commercial HTS EE panels were an accept-
able alternative to the standard pathway in terms of cost
effectiveness, with more diagnoses than the SDM and less
cost.
4 | DISCUSSION
This study uniquely compares diagnostic yield, cost effec-
tiveness, and clinical utility of the exome diagnostic
model (EDM) over the standard diagnostic model (SDM)
for patients with EE, who remain undiagnosed after first-
tier assessment. Our study focused on this group as they
have traditionally entered an unsatisfactory, prolonged,
costly, and invasive often unsuccessful “diagnostic odys-
sey.” We identified a need to assess the optimal pathway
in the HTS era, to inform clinical practice and guide
funding policies. This study reflects the type of patient
cohort identified by Doble et al. (2016) as most likely to
benefit from the early introduction of genomic testing to
clinical medicine.
Our results strongly support the EDM, which resulted
in a cost saving of AU$5,236 per additional diagnosis:
approximately 10 times less expensive per diagnosis than
the SDM. Sensitivity analysis demonstrated that the
majority of commercial ES platforms analyzed were also
cost-effective, highlighting the robustness of our findings.
We thus propose an optimal approach (Figure 5) for the
investigation of EE which benefits patients and their fami-
lies by reducing the length and invasiveness of the “diag-
nostic odyssey” and provides a cost saving for the health
budget.
The diagnostic yield of the EDM was 50% compared to
6% for the SDM. This diagnostic yield is consistent with
current literature (Helbig et al., 2016; Mercimek-Mahmuto-
glu et al., 2015) and reflects the large number of genetic
causes of EE (McTague et al., 2016), which the SDM is
ill-equipped to interrogate. We found, as others have, that a
trio, as opposed to singleton, ES approach resulted in a
high diagnostic yield: especially by facilitating detection of
autosomal recessive and novel variants (Lee et al., 2014;
Monroe et al., 2016). Our study also replicates other stud-
ies (Tarailo-Graovac et al., 2016) that point to limitations
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of biochemical screening for diagnosis of neurometabolic
causes of EE. Four patients received a diagnosis of a cryp-
tic metabolic condition despite prior nondiagnostic meta-
bolic screening (patients 1, 2, 13, 14 in Table 1). Although
the majority of identified causal genetic variants in EE are
autosomal and de novo (McTague et al., 2016), autosomal
recessive causes are increasingly recognized (Helbig et al.,
2016), as is germline mosaicism for dominant variants (Xu
et al., 2015). In our cohort, five (31.3%) of the 16 diag-
nosed patients had an inherited X-linked or autosomal
recessive cause. This has critical genetic counseling
implications.
The traditional “diagnostic odyssey” for EE patients can
take years to complete (Kamien et al., 2012; Mercimek-
Mahmutoglu et al., 2015). By comparison, the quoted turn-
around time for a commercial diagnostic trio ES is 6–
12 weeks (source GeneTests: www.genetests.org, accessed
June 2017). Therefore, ES can dramatically shorten the
time to diagnosis providing earlier potential for targeted
treatment/surveillance (Consortium E, 2015; Reif et al.,
2017). Additional diagnoses will allow an increased num-
ber of families to access specific support groups and accu-
rate genetic counseling, allowing options for antenatal and
preimplantation genetic diagnosis (Berkovic, 2015). In our
cohort, a diagnosis allowed several changes in manage-
ment, including changes in choice and weaning of
antiepileptic treatment, helped guide family planning, and
in some circumstances helped families to move from a
diagnostic to a palliative approach in the best interest of
their children (Table 1). Even for those who do not reach a
diagnosis through ES, there may be a deep satisfaction that
“all that is possible” is being done to find the cause of EE
(McGowan et al., 2013).
Although the cost of ES is falling, limited diagnostic
budgets and concerns regarding the chance of detecting an
incidental finding (IF) may mean that families and clini-
cians prefer to order a HTS gene panel (Chambers et al.,
2016) over ES. Simpler genetic counseling (with a time
and cost saving) is required for a panel than ES (Chambers
et al., 2016). We therefore compared the cost and antici-
pated diagnostic yield of two commercial HTS EE panels
with the SDM. Both assessed HTS panels were cost-effec-
tive compared to the standard diagnostic model with a cost
saving of AU$7,535 (95% CI: $2,278; $22,188) and AU
$16,387 (95% CI: $9,782; $35,120) per additional diagno-
sis (Table 2 and Figure 3). The anticipated diagnostic
yields reflect recent similar reported results (Mercimek-
Mahmutoglu et al., 2015; Trump et al., 2016), and demon-
strated that a larger number of genes in a panel did not
equate to a higher diagnostic yield, reflecting the impor-
tance of a tightly curated gene list (Chambers et al., 2016).
For example, not all panels included the recently described
EE genes DNM1 (616346), DYNC1H1 (614563), and
WWOX (616211). This comparative analysis shows that trio
ES leads to a greater diagnostic rate over multigene panel
as this is an unbiased genome-wide test which allows
detection of novel and very recently described genetic
causes of EE (Dyment et al., 2015; Helbig et al., 2016).
No incidental findings (IF) were detected in the course of
our study, unsurprisingly given the size of our cohort
(Amendola et al., 2015; Olfson et al., 2015). IF can also
result from HTS panels, for example, due to the overlap
between cardiac arrhythmia and epilepsy genes (Chambers
et al., 2016).
A major consideration in the genomic era is the rigor
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FIGURE 3 Cost-effectiveness plane
comparing “in-house” (SEALS) and four
commercial trio exome sequencing (ES)
platforms (Centogene, Nijmegen, GeneDx,
and Fulgent) to standard diagnostic
pathway
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variants or genes in order to provide a secure diagnosis
(Lee et al., 2014; McGowan et al., 2013; Monroe et al.,
2016; Tarailo-Graovac et al., 2016; Xu et al., 2015). The
cost of variant analysis was therefore a major component
of the cost of ES in our laboratory (Table S1) and the com-
mercial HTS platforms that were analyzed as part of our
sensitivity analysis. We utilized a conservative diagnostic-
grade approach to variant pathogenicity assessment, as rec-
ommended by international guidelines (Cartwright, 1997;
Joshi et al., 2016). This entailed diagnostic functional
assays, in silico prediction tools, literature review, interro-
gation of genomic databases of healthy and affected indi-
viduals (such as ExAC and ClinVar), and when required,
collaborative clinical and basic science research (Briggs
et al., 1997; Trump et al., 2016). It is envisaged that the
costs related to variant analysis are likely to reduce in the
future, as improved collaborative research and expanded
genomic databases provide accurate pathogenicity assess-
ments on more variants (Cartwright, 1997).
In considering our study design, we identified a need
to assess the optimal diagnostic pathway in the genomic
sequencing age, in order to inform best clinical practice
and guide health funding policy. Although the temptation
to opt for ES as a first-tier genetic test is strong, and in
some circumstances may be valid (Whole-exome sequenc-
ing strategy proposed as first-line test, 2016), it is clear
that with the complexities associated with genetic testing,
phenotypic/genotypic heterogeneity and unique nuances of
specific clinical situations, a well-thought-out approach is
required to result in optimal outcomes, in terms of patient
care and cost effectiveness. To this end, we have proposed
a diagnostic pathway (Figure 5) derived from the EDM
used in this study. We retain a first-tier diagnostic step to
allow for timely screening for rapidly diagnosable condi-
tions and disorders which would require an immediate
change in patient management. Multidisciplinary assess-
ment of neuroradiology in this first tier is increasingly rec-
ognized to be critical in assessing for subtle cortical
malformations that are less likely to have a germline
genetic cause (Berg et al., 2017), and we appreciate that
the access of all patients to such tertiary neuroradiology
review is not available in all centers, which could lead to
a reduction in diagnostic yield of second-tier testing. The
second-tier diagnostic step integrates ES or multigene
panel, as well as those additional tests required for a com-
prehensive second-tier evaluation (e.g., screening for
methylation abnormalities, triplet repeat and non-nuclear
mitochondrial disorders) and multidisciplinary team
(MDT) meetings. We also recommend pre- and posttest
counseling and reanalysis of the HTS data for undiag-
nosed patients, as this has been shown to lead to further
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We have demonstrated that a two-tier diagnostic
approach, incorporating trio ES as a second-tier test, offered
a significantly higher diagnostic yield and improved cost-
effectiveness compared to a standard diagnostic approach for
EE. We were able to show reproducibility of our findings by
analyzing costs and anticipated diagnostic yields associated
with commercial ES platforms and multigene panels. We
therefore propose that a high-throughput sequencing
approach, incorporating trio ES or gene panel, depending on
resources and patient and clinician preference, would be an
appropriate second-tier diagnostic step for patients with EE
who remain undiagnosed after first-tier testing (Figure 5),
with implications for clinical practice and health policy
(Monroe et al., 2016; Soden et al., 2014).
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